Citations for
1ATP13A2, EGLN1, HIF1A
Regulation of ATP13A2 via PHD2-HIF1α Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease.
Rajagopalan S, Rane A, Chinta SJ, Andersen JK.
J Neurosci 36(4):1086-95. doi: 10.1523/JNEUROSCI.3117-15.2016. 2016
2EGLN1
Identification of a Tibetan-specific mutation in the hypoxic gene EGLN1 and its contribution to high-altitude adaptation.
Xiang K, Ouzhuluobu, Peng Y, Yang Z, Zhang X, Cui C, Zhang H, Li M, Zhang Y, Bianba, Gonggalanzi, Basang, Ciwangsangbu, Wu T, Chen H, Shi H, Qi X, Su B.
Mol Biol Evol ol Biol Evol. 2013 May 10. [Epub ahead of print] 2013
3EGLN1
EGLN1 variants influence expression and SaO2 levels to associate with high-altitude pulmonary oedema and adaptation.
Mishra A, Mohammad G, Thinlas T, Pasha MA.
Clin Sci (Lond) 124(7):479-89. doi: 10.1042/CS20120371. 2013
4EGLN1, EGLN2, EGLN3
The regulation, localization, and functions of oxygen-sensing prolyl hydroxylase PHD3.
Jaakkola PM, Rantanen K.
Biol Chem 394(4):449-57. doi: 10.1515/hsz-2012-0330. Review. 2013
5EGLN1
Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity.
Leite de Oliveira R, Deschoemaeker S, Henze AT, Debackere K, Finisguerra V, Takeda Y, Roncal C, Dettori D, Tack E, Jönsson Y, Veschini L, Peeters A, Anisimov A, Hofmann M, Alitalo K, Baes M, D'hooge J, Carmeliet P, Mazzone M.
Cancer Cell 22(2):263-77. doi: 10.1016/j.ccr.2012.06.028. 2012
6EGLN1, VHL
Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S, Najrana T, Toth K, Cao S, Durrani FA, Pili R, Rustum YM.
BMC Cancer 12:293. doi: 10.1186/1471-2407-12-293. 2012
7EGLN1
Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer.
Su Y, Loos M, Giese N, Metzen E, Büchler MW, Friess H, Kornberg A, Büchler P.
Cancer 118(4):960-72. doi: 10.1002/cncr.26344. Epub 2011 Jul 26. 2012
8EGLN1, EGLN2, EGLN3
Molecular cloning of phd1 and comparative analysis of phd1, 2, and 3 expression in Xenopus laevis.
Han D, Wen L, Chen Y.
ScientificWorldJournal 2012:689287. doi: 10.1100/2012/689287. Epub 2012 May 3. 2012
9EGLN1
Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis.
Takeda Y, Costa S, Delamarre E, Roncal C, Leite de Oliveira R, Squadrito ML, Finisguerra V, Deschoemaeker S, Bruyère F, Wenes M, Hamm A, Serneels J, Magat J, Bhattacharyya T, Anisimov A, Jordan BF, Alitalo K, Maxwell P, Gallez B, Zhuang ZW, Saito Y, Simons M, De Palma M, Mazzone M.
Nature 479(7371):122-6. doi: 10.1038/nature10507. 2011
10EGLN1
Studies on the reaction of nitric oxide with the hypoxia-inducible factor prolyl hydroxylase domain 2 (EGLN1).
Chowdhury R, Flashman E, Mecinović J, Kramer HB, Kessler BM, Frapart YM, Boucher JL, Clifton IJ, McDonough MA, Schofield CJ.
J Mol Biol 410(2):268-79. doi: 10.1016/j.jmb.2011.04.075. Epub 2011 May 13. 2011
11EGLN1
Prolyl hydroxylase domain protein 2 (PHD2) mediates oxygen-induced retinopathy in neonatal mice.
Duan LJ, Takeda K, Fong GH.
Am J Pathol 178(4):1881-90. doi: 10.1016/j.ajpath.2010.12.016. 2011
12EGLN1
Prolyl hydroxylase 2: a novel regulator of β2 -adrenoceptor internalization.
Yan B, Huo Z, Liu Y, Lin X, Li J, Peng L, Zhao H, Zhou ZN, Liang X, Liu Y, Zhu W, Liang D, Li L, Sun Y, Cui J, Chen YH.
J Cell Mol Med 15(12):2712-22. doi: 10.1111/j.1582-4934.2011.01268.x. 2011
13ATF4, EGLN1, EGLN2, EGLN3
PHD1 interacts with ATF4 and negatively regulates its transcriptional activity without prolyl hydroxylation.
Hiwatashi Y, Kanno K, Takasaki C, Goryo K, Sato T, Torii S, Sogawa K, Yasumoto K.
Exp Cell Res 317(20):2789-99. doi: 10.1016/j.yexcr.2011.09.005. Epub 2011 Sep 17. 2011
14EGLN1
EGLN1 involvement in high-altitude adaptation revealed through genetic analysis of extreme constitution types defined in Ayurveda.
Aggarwal S, Negi S, Jha P, Singh PK, Stobdan T, Pasha MA, Ghosh S, Agrawal A; Indian Genome Variation Consortium, Prasher B, Mukerji M.
Proc Natl Acad Sci U S A 107(44):18961-6. doi: 10.1073/pnas.1006108107. Epub 2010 Oct 18. 2010
15EGLN1
PHD2 in tumour angiogenesis.
Chan DA, Giaccia AJ.
Br J Cancer 103(1):1-5. doi: 10.1038/sj.bjc.6605682. Epub 2010 May 11. Review. 2010
16EGLN1
Retention of prolyl hydroxylase PHD2 in the cytoplasm prevents PHD2-induced anchorage-independent carcinoma cell growth.
Jokilehto T, Högel H, Heikkinen P, Rantanen K, Elenius K, Sundström J, Jaakkola PM.
Exp Cell Res 316(7):1169-78. doi: 10.1016/j.yexcr.2010.02.012. Epub 2010 Feb 12. 2010
17ECYT1, ECYT2, ECYT3, ECYT4, EGLN1, EPAS1, EPOR, VHL
Genetic origins and clinical phenotype of familial and acquired erythrocytosis and thrombocytosis.
Percy MJ, Rumi E.
Am J Hematol 84(1):46-54. Review. 2009
18EGLN1
Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization.
Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA, Pollard P, Ruiz de Almodovar C, De Smet F, Vinckier S, Aragonés J, Debackere K, Luttun A, Wyns S, Jordan B, Pisacane A, Gallez B, Lampugnani MG, Dejana E, Simons M, Ratcliffe P, Maxwell P, Carmeliet P.
Cell 136(5):839-51. Epub 2009 Feb 12. 2009
19EGLN1, EGLN2, EGLN3
Role of the intracellular localization of HIF-prolyl hydroxylases.
Yasumoto K, Kowata Y, Yoshida A, Torii S, Sogawa K.
Biochim Biophys Acta 1793(5):792-7. Epub 2009 Feb 5. 2009
20EGLN1, FKBP8
Hypoxia-inducible Factor Prolyl-4-hydroxylase PHD2 Protein Abundance Depends on Integral Membrane Anchoring of FKBP38.
Barth S, Edlich F, Berchner-Pfannschmidt U, Gneuss S, Jahreis G, Hasgall PA, Fandrey J, Wenger RH, Camenisch G.
J Biol Chem 284(34):23046-58. Epub 2009 Jun 22. 2009
21ECYT1, ECYT2, ECYT3, ECYT4, EGLN1, EPAS1, EPOR, VHL
A study of 36 unrelated cases with pure erythrocytosis revealed three new mutations in the erythropoietin receptor gene.
Al-Sheikh M, Mazurier E, Gardie B, Casadevall N, Galactéros F, Goossens M, Wajcman H, Préhu C, Ugo V.
Haematologica 93(7):1072-5. Epub 2008 May 19. 2008
22ECYT3, EGLN1
PHD2 mutation and congenital erythrocytosis with paraganglioma.
Ladroue C, Carcenac R, Leporrier M, Gad S, Le Hello C, Galateau-Salle F, Feunteun J, Pouysségur J, Richard S, Gardie B.
N Engl J Med 359(25):2685-92. 2008
23ECYT3, EGLN1
A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis.
Percy MJ, Zhao Q, Flores A, Harrison C, Lappin TR, Maxwell PH, McMullin MF, Lee FS.
Proc Natl Acad Sci U S A 103(3):654-9. Epub 2006 Jan 9. 2006
24EGLN1, EGLN2, EGLN3
Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor.
Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM.
J Biol Chem 279(37):38458-65. Epub 2004 Jul 7. 2004
25EGLN1, EGLN2, EGLN3
Mammalian EGLN genes have distinct patterns of mRNA expression and regulation.
Lieb ME, Menzies K, Moschella MC, Ni R, Taubman MB.
Biochem Cell Biol 80(4):421-6. 2002
26EGLN1, EGLN2
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.
Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ.
Cell 107(1):43-54. 2001
27EGLN1, EGLN2, EGLN3, SCAND2
Characterization and comparative analysis of the EGLN gene family.
Taylor MS.
Gene 275(1):125-32. 2001
28EGLN1
SM-20 is a novel mitochondrial protein that causes caspase-dependent cell death in nerve growth factor-dependent neurons.
Lipscomb EA, Sarmiere PD, Freeman RS.
J Biol Chem 276(7):5085-92. 2001
29EGLN1, SCAND2
Mapping, characterization, and expression analysis of the SM-20 human homologue, c1orf12, and identification of a novel related gene, SCAND2
Dupuy D, Aubert I, Duperat VG, Petit J, Taine L, Stef M, Bloch B, Arveiler B.
Genomics 69(3):348-54. 2000
30MAFD3, EGLN1
Association within a family of a balanced autosomal translocation with major mental illness.
St Clair D, Blackwood D, Muir W, Carothers A, Walker M, Spowart G, Gosden C, Evans HJ.
Lancet 336(8706):13-6. 1990